Nektar Therapeutics sell JPMorgan Chase & Co.
Start price
20.11.23
/
50%
€0.47
Target price
20.11.24
-
Performance (%)
98.40%
End price
21.11.24
€0.93
Summary
This prediction ended on 21.11.24 with a price of €0.93. The SELL prediction by JPMorgan_Chase___Co_ for Nektar Therapeutics was trending in the completely wrong direction and closed with a performance of 98.40%. JPMorgan_Chase___Co_ has 50% into this predictionNektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Nektar Therapeutics | - | - | - |
| iShares Core DAX® | -1.212% | 1.925% | 17.589% |
| iShares Nasdaq 100 | -4.714% | -1.810% | 0.450% |
| iShares Nikkei 225® | -2.976% | -2.660% | 10.156% |
| iShares S&P 500 | -2.744% | -0.448% | 0.320% |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread Discuss Nektar Therapeutics
Nektar Therapeutics (NASDAQ: NKTR) had its "underweight" rating re-affirmed by analysts at JPMorgan Chase & Co..
Ratings data for NKTR provided by MarketBeat
In the thread Trading Nektar Therapeutics
Die von JPMorgan_Chase___Co_ gewählte maximale Laufzeit wurde überschritten